Markus Johnsson

USPTO Granted Patents = 35 (Patent Applications = 34)

CIPO Patents = 15 (Patent Applications = 7)

EPO Patents = 18 (Patent Applications = 22)

Average Co-Inventor Count = 3.1

ph-index = 8

Forward Citations = 243(Granted Patents)

Company Filing History:

Years Active: 2012-2025

Loading Chart...

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12396944 - Injectable buprenorphine formulation (2025-08-26),

2. 12318379 - Opioid formulations (2025-06-03),

3. 12257282 - Mixtures and formulations (2025-03-25),

4. 12246055 - Lipid-controlled release compositions (2025-03-11),

5. 12161640 - Opioid formulations (2024-12-10),

6. 12029813 - Injectable buprenorphine formulation (2024-07-09),

7. 11672843 - Somatostatin receptor agonist formulations (2023-06-13),

8. 11564968 - Formulations containing a somatostatin receptor agonist (2023-01-31),

9. 11433120 - Controlled release peptide formulations (2022-09-06),

10. 11369617 - Prostacyclin analogue formulations (2022-06-28),

11. 11241476 - Mixtures and formulations comprising an alkyl ammonium EDTA salt (2022-02-08),

12. 11135264 - Formulations containing a somatostatin receptor agonist (2021-10-05),

13. 11135215 - Opioid formulations (2021-10-05),

14. 11110084 - Opioid formulations (2021-09-07),

15. 10912772 - Opioid formulations (2021-02-09),

Title: Innovations in Opioid Management: The Patents of Markus Johnsson

Introduction: Markus Johnsson, based in Lund, Sweden, is a prolific inventor with a remarkable portfolio of 31 patents to his name. His work primarily focuses on the development of innovative formulations for opioid medications, contributing significantly to pain management and opioid maintenance therapies.

Latest Patents: Among his latest innovations are two significant patents. The first patent covers a depot precursor formulation designed for opioid treatment, which includes a controlled-release matrix and specific organic solvents. This formulation incorporates at least 12% by weight of active agents selected from buprenorphine and its salts, providing effective pain management solutions via opioid maintenance methods.

The second patent presents an injectable buprenorphine formulation, consisting of a lipid-controlled release matrix that includes at least 50% triacyl lipids. Additionally, this invention contains at least 16% by weight of the active agent, buprenorphine, calculated as the free base. This liquid composition facilitates the treatment of pain, offering new pathways for opioid maintenance therapy and aiding in the management of withdrawal symptoms from opioids and cocaine.

Career Highlights: Markus Johnsson has made significant contributions to the field through his research and development initiatives while working at renowned companies such as Camurus AB and Camarus AB. His innovative approaches to opioid formulations have positioned him as a key figure in the pharmaceutical industry.

Collaborations: Throughout his career, Markus has collaborated with notable professionals such as Fredrik Tiberg and Catalin Nistor. Their collective expertise has fostered advancements in opioid formulation technologies, enhancing the efficacy and safety of pain management therapies.

Conclusion: Markus Johnsson's dedication to innovation in opioid management is evident through his numerous patents and impactful collaborations. His work continues to shape the future of pain management and opioid therapies, providing essential solutions for both patients and healthcare providers.

This text is generated by artificial intelligence and may not be accurate.